Diagnosis: Familial Hypercholesterolemia (FH) or Polygenic Hypercholesterolemia
The most likely diagnosis for isolated elevation of total cholesterol with all other labs normal is familial hypercholesterolemia (FH), particularly if LDL-C is ≥190 mg/dL (≥4.9 mmol/L), though polygenic hypercholesterolemia is statistically more common at this threshold. 1
Diagnostic Approach
Initial Assessment
When you encounter isolated elevated total cholesterol, immediately calculate or measure LDL-C:
- If LDL-C ≥190 mg/dL (≥4.9 mmol/L): This triggers suspicion for heterozygous FH, even though most cases at this level are actually polygenic hypercholesterolemia 1
- If LDL-C 160-189 mg/dL: Consider polygenic causes or milder FH variants
- If LDL-C <160 mg/dL: Less likely to be monogenic FH, but genetic testing may still be warranted if strong family history exists 2
Critical Pitfall to Avoid
Do not assume "normal" or mildly elevated LDL-C excludes FH. A case report demonstrates that genetic FH can present with LDL-C <130 mg/dL after dietary intervention, yet the patient carried the same pathogenic variants as family members with classic presentations 2. This underscores why family history and genetic testing trump absolute LDL-C values.
Exclude Secondary Causes First
Before diagnosing primary dyslipidemia, rule out:
- Hypothyroidism (check TSH)
- Nephrotic syndrome (check urinalysis, creatinine)
- Cholestatic liver disease (check liver enzymes, bilirubin)
- Medications (thiazides, beta-blockers, corticosteroids)
- Poorly controlled diabetes
- Pregnancy 3, 1
When to Pursue Genetic Testing
Genetic testing should be performed when: 3, 1
- LDL-C ≥190 mg/dL (at 95th percentile or higher)
- Presence of tendon xanthomas at any LDL-C level
- Strong family history of premature ASCVD or high cholesterol
- For cascade testing when a family member has confirmed FH
Genetic Testing Strategy
Before ordering expensive genetic testing, use a clinical scoring system to assess pre-test probability:
- Dutch Lipid Clinic Network algorithm
- Simon Broome criteria
- MEDPED criteria 1
The genetic panel should screen for pathogenic variants in:
- LDLR (most common, >50% of FH cases)
- APOB (second most common, ~45% of detected variants)
- PCSK9 (gain-of-function, rare)
- LDLRAP1 (very rare)
- Plus polygenic risk score 1
Important Nuances
The Polygenic Reality
Most patients with LDL-C 190-250 mg/dL have polygenic hypercholesterolemia, not monogenic FH 1. Genetic testing increasingly returns high polygenic scores rather than single pathogenic variants. Polygenic hypercholesterolemia carries:
- Lower cardiovascular risk than monogenic FH
- Higher risk than general population
- Still warrants aggressive lipid-lowering therapy
Physical Examination Clues
Look specifically for:
- Tendon xanthomas (Achilles, extensor tendons of hands) - highly specific for FH
- Corneal arcus before age 45
- Xanthelasmas (less specific)
If tendon xanthomas present with only modest LDL-C elevation (not severely elevated), consider rare diagnoses:
- Sitosterolemia (check plasma plant sterols)
- Cerebrotendinous xanthomatosis (check bile alcohols, look for neurologic symptoms) 1
Treatment Implications
Regardless of whether genetic testing confirms monogenic FH or suggests polygenic etiology:
- LDL-C ≥190 mg/dL warrants statin therapy without requiring risk calculation
- Target LDL-C <70 mg/dL (1.8 mmol/L) or ≥50% reduction, whichever is lower, for optimal ASCVD prevention 1
- Confirmed genetic FH justifies more aggressive therapy and earlier intervention
- Positive genetic diagnosis enables cascade screening of first-degree relatives 3
Cascade Testing Protocol
When FH is genetically confirmed in the index case:
- Test all first-degree relatives
- Use age-specific, sex-specific LDL-C thresholds for phenotypic diagnosis in relatives
- Measure LDL-C fasting on two separate occasions 3